Recombinant influenza virus vaccine tetravalent - Adimmune CorporationAlternative Names: Tetravalent influenza vaccine - Adimmune
Latest Information Update: 08 Nov 2016
At a glance
- Originator Adimmune Corporation
- Developer Adimmune Corporation; Protein Sciences Corporation
- Class Anti-infectives; Influenza virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Registered Influenza virus infections